Peptilogics’ Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting Highlight Peptide Therapeutic PLG0206 for the Treatment of Periprosthetic Joint Infection (PJI)

March 2022

Peptilogics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Trial of PLG0206 in Periprosthetic Joint Infection

January 2022

Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis

January 2022

Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection

December 2021

Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021

September 2021

Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy

April 2021